Logo

Ciphergen Hires Emergo to Help Win CE Mark for Ovarian Cancer IVD

Dec 19, 2006
NEW YORK (GenomeWeb News) — Ciphergen has hired European international standards consulting company Emergo to help it win CE Mark clearance for its ovarian cancer in vitro diagnostic, the company said today.
 
The company said it also is preparing a clinical trial toward gaining clearance with the US Food and Drug Administration.
 
Under the agreement, Emergo will serve as a liaison with the European Ministries of Health to help Ciphergen earn Good Manufacturing Practices approval. Ciphergen said this will enable it to market the test in at least one European country in 2007.  
 
The test uses a panel of biomarkers that provide information that may help oncologists stratify risk of developing ovarian cancer. It would be used in medical triage for differentiating malignant and benign pelvic masses.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.